Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 10 01 2024
revised: 10 03 2024
accepted: 11 03 2024
pubmed: 5 4 2024
medline: 5 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

Glucose-like peptide-1-receptor agonists (GLP-1RAs) have become integral to the management of type 2 diabetes and obesity. GLP-1RAs work in part through delaying gastric emptying, raising concerns about retained gastric contents (RGC) during esophagogastroduodenoscopy (EGD).

Identifiants

pubmed: 38574832
pii: S1542-3565(24)00295-7
doi: 10.1016/j.cgh.2024.03.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Roberto Simons-Linares (R)
W Scott Butsch (WS)

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

S A Firkins (SA)

Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: firkins@ccf.org.

J Yates (J)

Community Care Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

N Shukla (N)

Community Care Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

R Garg (R)

Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

J Vargo (J)

Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

A Lembo (A)

Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Classifications MeSH